Helping the Fight Against TB: Researchers Solve Decade Long Mystery
A false color scanning electron microscopy image of Mycobacterium bovis BCG. Credit: Photo taken by Dr Julian Thorpe of the University of Sussex and Dr Simon Waddell of the Brighton and Sussex Medical School.
Scientists have solved a decade-old mystery that could eventually lead to the development of earlier treatments for one of the world’s deadliest diseases, which affects up to 2 billion people.
Research carried out by the University of Sussex and the Polish Academy of Sciences has identified two key proteins that allow mycobacterium tuberculosis, the causative agent of tuberculosis (TB), to “lay low” within cells designed to destroy them.
More than 10.6 million people worldwide fell ill and 1.7 million died from tuberculosis last year while a quarter of the world has latent TB, which will develop into active tuberculosis for one in ten victims years or even decades later. TB is notoriously difficult to treat with current drug treatments often producing debilitating side effects within patients, including muscle wastage and loss of sight.
Previously, the Doherty group at the University of Sussex’s Genome Damage and Stability Centre discovered that mycobacteria repair DNA breaks using an enzyme complex called Ligase D (LigD). The latest study establishes that a closely related protein apparatus called Ligase C, whose function was unclear until now, combines with other repair proteins to fix damaged DNA bases in mycobacterial genomes caused by the attack of oxygen free radicals.
Deleting LigC reduced mycobacteria’s ability to repair and survive oxidiative DNA damage. Deleting both LigC and D lowered their survival rate even further, suggesting that inhibiting these repair mechanisms could be exploited to develop novel anti-microbial strategies.
Prof. Aidan Doherty hopes this discovery will aid in the designing of new antibiotics that could help target mycobacteria, particularly during their latent phase.
He added: “Mycobacteria are incredibly resilient and can remain dormant for many years inside cells where they are exposed to significant levels of free radical damage designed to kill foreign “invaders”. However, these bacteria survive using complex repair mechanisms that protect their genomes from these attacks.
“We have shown that by removing LigC and D, mycobacterial cells become much more sensitive to oxidative damage. With further investigation of these protective mechanisms, it is hoped that this research will pave the way for the development of new drugs to more successfully target mycobacteria.”
Dr Simon Waddell, a senior lecturer in microbial pathogenesis at the Sussex and Brighton Medical School, said: “‘This study defines a new DNA repair pathway in mycobacteria, a greater understanding of such fundamental bacterial systems may lead to new drug therapies and strategies to prevent the emergence of drug-resistant tuberculosis.”
This article has been republished from materials provided by the University of Sussex. Note: material may have been edited for length and content. For further information, please contact the cited source.
Płociński, P., Brissett, N. C., Bianchi, J., Brzostek, A., Korycka-Machała, M., Dziembowski, A., . . . Doherty, A. J. (2017). DNA Ligase C and Prim-PolC participate in base excision repair in mycobacteria. Nature Communications, 8(1). doi:10.1038/s41467-017-01365-y
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE